



## Investigation of adherent-invasive *E. coli* in patients with Crohn's disease

Akram Sarabi Asiabar<sup>1</sup>, Hamid Asadzadeh Aghdai<sup>2</sup>, Azar Sabokbar<sup>1</sup>, Mohammad Reza Zali<sup>3</sup>, Mohammad Mehdi Feizabadi<sup>\*4</sup>

Received: 25 Jul 2017

Published: 11 Feb 2018

### Abstract

**Background:** Crohn's disease and Ulcerative colitis are known as inflammatory bowel disease with high morbidity which are as a result of increasing immune responses to intestinal microbiota in genetically susceptible individuals. The association of adherent invasive *Escherichia coli* with Crohn's disease in human has been discussed for decades. The principal aim of this study was to assess the relationship between adherent invasive *Escherichia coli* in Iranian patients with Crohn's disease.

**Methods:** The presence of adherent invasive *Escherichia coli* DNA and viable adherent invasive *Escherichia coli* cells were identified through PCR and conventional culture methods, respectively. All the specimens were subsequently cultured in Hi Chrome Agar medium.

**Results:** Using molecular assay, the invasive plasmid antigen H and invasion-association locus genes were detected from tissue samples confirming the presence of adherent-invasive *Escherichia coli*. The invasive plasmid antigen H was detected in 46.7% of CD and 13.3% of healthy peoples. The invasion-association locus gene was found in 36.7% of patients with Crohn's disease and 10% in individuals without IBD.

**Conclusion:** This study demonstrated an increased frequency of adherent invasive *E. coli* with invasive plasmid antigen H and invasion-association locus genes from patients with CD in comparison to control individuals. Moreover, it was shown that adherent invasive *E. coli* with the invasive plasmid antigen H and invasion-association locus genes can act as a predisposing factor in the development of IBD.

**Keywords:** Crohn Disease, Inflammatory bowel disease, *Escherichia coli*, PCR

Copyright© Iran University of Medical Sciences

**Cite this article as:** Sarabi Asiabar A, Asadzadeh Aghdai H, Sabokbar A, Zali MR, Feizabadi MM. Investigation of adherent-invasive *E. coli* in patients with Crohn's disease. *Med J Islam Repub Iran.* 2018(11 Feb);32:11. <https://doi.org/10.14196/mjiri.32.11>

### Introduction

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder divided into Ulcerative colitis (UC) and Crohn's disease (CD) (1, 2). The rising trend of the disease has been observed in Middle Eastern countries as well as in other parts of the world and statistics shows the incidence also is on the rises in North America and Europe as well as other parts of the world. Likewise, a recent study demonstrated that the prevalence of IBD is increasing dramatically in Iran (3).

The incidence and prevalence of ulcerative colitis and

Crohn's disease have been increased all over the world, especially among children and adults. It is believed that several factors such as immunology, genetic factors, stress, diet, being an alcoholic or a smoker, as well as bacteria such as the adherent-invasive strains of *Escherichia coli*, *Campylobacter spp.*, *Clostridium difficile*, *Mycobacterium avium* subspecies *Paratuberculosis*, and *Bacteroides fragilis* (4-7) may play a role in the development of IBD. Since gastrointestinal (GI) tract of healthy people is colonized by a wide variety of different microorganisms

**Corresponding author:** Dr Mohammad Mehdi Feizabadi, [mfeizabadi@tums.ac.ir](mailto:mfeizabadi@tums.ac.ir)

<sup>1</sup> Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, Iran.

<sup>2</sup> Basic and Molecular Epidemiology of Gastroenterology Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

<sup>3</sup> Department of Inflammatory Bowel Disease, Research Center for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

<sup>4</sup> Department of Microbiology, School of Medicine, Tehran University of Medical Science, Tehran, Iran, & Thoracic Research Center, Imam Khomeini Hospital, Tehran, Iran.

#### ↑What is "already known" in this topic:

Inflammatory bowel disease (IBD) is comprised of Crohn's disease (CD) and Ulcerative colitis (UC). The prevalence and incidence of IBD are continuously rising in Iran. No study has been conducted to investigate the role of adherent invasive *E. coli* in patients with Crohn's disease occurred in the country.

#### →What this article adds:

Due to the rising trend of IBD prevalence and incidence in Iran, and also the significant role of intestinal microbiota in the development of disease, further investigation into the possible causing factors is vitally imperative.

hence, dysbiosis of the intestinal microbiota is likely cause of IBD (8).

It is known that intestinal bacteria can cause CEA-CAM6 expression through inducing inflammatory cytokines. The expression can then leads to production of *E. coli* with AIEC phenotype. The AIEC can attach to epithelial cells by a mechanism involving polymerization of microtubules. In fact, AIEC adheres to GP2 (glycoprotein 2) upon M cells by LPF (long polar fimbriae) and enter to Peyer's patches and exacerbates inflammation in the intestine (9). Moreover, AIEC able to adhere epithelial cells and invade into the cytoplasmic eukaryotic infectious cells with type 1 fimbriae (*fimH*), invasive plasmid antigen H (*ipaH*) and invasion-association locus (*ial*) (10).

However, *E. coli* with adherent-invasive phenotype should be regarded as a separate issue of pathogenicity of *E. coli* causing inflammation in the human intestine.

The principal purpose of this study was to investigate of *E. coli* with adherent-invasive phenotype and their relation to Crohn's disease.

## Methods

In the present study, sixty subjects including thirty patients with lesions of Crohn's colitis and thirty people without IBD were collected during colonoscopy examinations. Samples with CD were obtained from lesions of colon, or terminal ileum. Moreover, the biopsy of control group was performed on normal areas. DNA was extracted from the tissue samples and PCR assay performed by targeting *ipaH* and *ial* genes. CD diagnosis based on clinical symptoms, laboratory evaluations, and colonoscopy finding was confirmed by histological assessment. The control subjects were taken from people with non-inflammatory IBD (nIBD). None of the individuals presented in this study used antibiotics or probiotics for the 3 months prior to the study. The study was accepted by the ethics committee of Tehran University Medical Sciences.

## Microbial identification

Samples were immediately transferred into sterile vials containing either thioglycolate broth or saline (Sigma-Aldrich, Hi Media) and stored at -20°C. The tissue biopsy were homogenized and inoculated into Hi Chrome *E. coli* agar (Sigma-Aldrich, Hi Media) and incubated for 18-24h

at 35±2°C. The bacteria were stored in TSB broth containing 30% glycerol at a temperature of -70°C for further analysis.

## DNA Extraction

Tissue biopsies were crushed and DNA extracted through RTP<sup>®</sup> Mycobacteria kit (Berlin, Germany).

## PCR assay

All samples were tested for the presence of *ipaH* and *ial* genes using molecular PCR. The nucleotide sequence of primers (Macrogen, Pishgam) and production size (base pairs) for amplification of the *ipaH* and *ial* genes are shown in Table 1 (11, 12). PCR was performed in 12.5µL comprising 5µL master mix (Amplicon, Pishgam), 0.5 µL of each primer, 2 µL of the DNA template (50 ng) and 4.5µL of ddH<sub>2</sub>O. Subsequently, the thermal cycling status was used: 300 seconds at 94°C and 25 cycles of amplification consisting of 60 seconds at 95°C, 55 seconds at 58°C, and 60 seconds at 72°C, with 300 seconds at 72°C for the final extension. PCR products were investigated by electrophoresis on a 1% agarose gel in 1X TBE buffer [10.8 g Tris and 5.5 g Boric acid, 0.5 M Na<sub>2</sub>EDTA (pH 8.0)] (13).

## Statistical Analysis

Data were analyzed using Pearson Chi-Square test, and *P* value below 0.05 considered as statistically significant.

## Results

### Clinical information of patients and controls

The average age of patients with IBD and controls were 38.8 and 52.86 years old respectively. The participants included 14 males and 16 female patients with CD, and 18 males and 12 females without IBD. In addition, the age range for patients with CD and without IBD was 18-64 and 25-76 years old respectively.

### Detection of adherent-invasive *E. coli* with *ipaH* and *ial* genes

Of 60 tissue samples collected, *E. coli* were isolated from 20 (66.6%) patients with CD and 22 (73.3%) from healthy people (Table 2). All isolated bacteria were confirmed as AIEC by biochemical tests and PCR assay. The

Table 1. The primers used for PCR reaction

Genes	Nucleotide Sequences(5'-3')	Size of product, bp
ipaH	F-GTTCCCTTGACCGCCTTCCGATACCGTC	619
	R-GCCGGTCAGCCACCCTCTGAGAGTAC	
ial	F-CTGGATGGTATGGTGAGG	320
	R-GGAGGCCAACAAATTATTCC	

Table 2. *E. coli* Bacterial Culture in various condition

Group	Culture of		Total
	Positive	Negative	
Crohn's disease			
Count	10	20	30
CD (%)	33.4	66.6	100.00
nIBD			
Count	8	22	
nIBD (%)	26.7	73.3	100.00
Total			
Count	18	42	60
Total (%)	30	70	100.00



Fig. 1. Amplification of the *ipaH* gene. Lanes: 1, DNA molecular size marker (100-bp ladder); 2-7, Crohn's disease samples; 8, negative control (Water).




Fig. 2. Amplification of the *ial* gene. Lanes: 1, DNA molecular size marker (100-bp ladder); 2-7, Crohn's disease samples; 8, negative control (Water).

*ipaH*, *ial* genes were amplified by utilizing particular primers and become visible as a band of approximately 619 and 320 kb on agarose gel respectively (Figs. 1 and 2). The difference between patients with Crohn's disease and controls was not significant ( $p=0.59$ ). Of 30 patients with CD, the positive and negative rate of *ipaH* gene was 46.7% ( $n=14$ ) and 53.3% ( $n=16$ ) respectively.

Table 3. PCR Analysis of the *ipaH* gene for CD and nIBD samples

Group	<i>ipaH</i>	
	Positive	Negative
Crohn's disease		
Count	14	16
CD (%)	46.7	53.3
P value	.005*	
nIBD		
Count	4	26
nIBD (%)	13.3	86.7
P value	0.24	

\*Significant at  $\alpha=0.05$

Table 4. PCR Analysis of the *ial* gene from CD and nIBD samples

Group	<i>ial</i>	
	Positive	Negative
Crohn's disease		
Count	11	19
CD (%)	36.7	63.3
P value	.015*	
nIBD		
Count	3	27
nIBD (%)	10.0	90.0
P value	0.34	

The percentage of *ipaH* among 30 individuals without IBD was 13.3% ( $n=4$ ) but 86.6% ( $n=26$ ) was not detected (Table 3). Furthermore, the positivity of *ial* gene were 36.7% ( $n=11$ ) and 10% ( $n=3$ ) in patients with CD and healthy people respectively (Table 4). Moreover, the presence of *ipaH* and *ial* genes in adherent-invasive *E. coli* in patients with CD was more than control populations.

Due to its high sensitivity, PCR assay was more reliable than cultivation. The difference between the correlation of adherent-invasive *E. coli* with *ipaH* and *ial* in CD patients with control populations was statistically significant ( $p<0.05$ ). All positive amplified fragments were sequenced and high percentage of adherent-invasive *E. coli* was identified.

Furthermore, a chi square test was performed and the correlation between adherent-invasive *E. coli* with *ipaH* and *ial* genes in patients with CD found to be ( $N=30$ ) =7.937,  $p=.005$  and ( $N=30$ ) =5.963,  $p=.015$  respectively. Nonetheless all positive amplified fragments were sequenced and high percentage of adherent-invasive *E. coli* was detected.

### Discussion

Crohn's disease is considered as a chronic inflammatory of GI disorder.

Although the etiology of inflammatory bowel disease is not still known (14), but numerous studies demonstrated that the mortality rate of this disease is high (15). Furthermore, it is demonstrated that several factors may play role in induction of the disease. In a research by Sartor RB et al, the intestinal microbiota effect on epithelial cells, and inflammation of the intestinal mucosa have shown to trigger the pathogenesis of both CD and UC (16). Moreover, CD patients demonstrated an altered intestinal microbial community, with different kind of bacteria in colonic and ileal areas (17).

Previous studies showed that *Enterobacteriaceae* especially *E. coli* could contributed the onset of IBD. Nevertheless other bacteria can trigger the pathogenesis of in-

inflammatory bowel disease including Bacteroidales, Clostridiales, Pasteurellaceae (*Haemophilus* sp.), Veillonellaceae, Neisseriaceae, and Fusobacteriaceae (18). Significant information exists regarding the role of adherent invasive *E. coli* in the CD. Numerous studies reported that adherent invasive *E. coli* could be a candidate for the development of CD (19).

An emerging evidence indicated an association between adherent invasive *E. coli* with IBD and colorectal cancer (20, 21 and 22). The present study shows no difference in the incidence of *E. coli* positive culture between CD and control patients (Table 2). The lack of *E. coli* in some tissue sample was probably due to consumption of antibiotics which in turn can cause dysbiosis in the human gastrointestinal tract (23). In some studies, using the culture-based method demonstrated that *E. coli* bacteria were found in the intestinal mucosa as well as in ulcers of both CD and UC patients compared to controls (24). In comparison with nIBD, our finding shows that the abundance of adherent invasive *E. coli* harboring *ipaH* and *ial* genes was higher in CD individuals. Additionally, we found that 46.7% and 36.7% of CD specimens harbored *ipaH* and *ial*, an increased proportion of AIEC, compared to control individuals. In spite of interesting debate, Dogan et al conducted a similar prevalence of AIEC in the ileum of patients with CD (25). Several studies showed a high proportion of AIEC harboring *fimH*, *fimA* and *Cas* genes in CD (26, 27). According to the present study, in comparison with nIBD, PCR assay displayed a high abundance of *ipaH* and *ial* genes in CD patients with statistically significant difference. These data proposed that AIEC most likely harbored *ipaH* and *ial* genes which in turn could be effective in the initiation of the CD. Nonetheless, since other virulence factors for AIEC were not analyzed, so it may be taken into consideration in the future study.

### Conclusion

Despite the role of several factors in the progression of IBD, the present study displays a high prevalence of AIEC with *ipaH* and *ial* from patients with CD. According to these findings, *E. coli* with AIEC phenotype could be a predisposing factor in the development of inflammatory bowel disease. In addition to AIEC, host immune response, genetics of patients and environmental factors play an important role in the initiation of IBD. Therefore the present study suggests that appropriate treatment against AIEC could be practically effective in patients with inflammatory bowel disease.

### Acknowledgments

We would like to thank the Behbood clinical staff for their kind cooperation. This study is supported by the Tehran University of Medical Sciences.

### Funding/Support

This study was supported in part by grant No. 33309 provided by Tehran University of Medical Sciences.

### Conflict of Interests

The authors declare that they have no competing interests.

### References

- Balfour Sartor MDR, Mazmanian SK. Intestinal Microbes in Inflammatory Bowel Diseases. *Am J Gastroenterol Suppl.* 2012 Jul;1(1):15.
- Vaishnava S, Behrendt CL, Ismail AS, Eckmann L, Hooper LV. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. *Proc Natl Acad Sci.* 2008;105(52):20858-20863.
- Taghavi SA, Safarpour AR, Hosseini SV, Noroozi H, Safarpour M, Rahimikazerooni S. Epidemiology of inflammatory bowel diseases (IBD) in Iran: a review of 740 patients in Fars Province, Southern Iran. *Ann Colorectal Res.* 2013;1(1):17-22.
- Ng SC, Tang W, Leong RW, Chen M, Ko Y, Studd C, et al. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. *Gut.* 2014.
- Hold GL, Smith M, Grange C, Watt ER, El-Omar EM. Role of the gut microbiota in inflammatory bowel disease pathogenesis: What have we learnt in the past 10 years? *World J Gastroenterol.* 2014;20(5):1192-1210.
- Ahmed I, Roy BC, Khan SA, Septer S, Umar S. Microbiome, metabolism and inflammatory bowel disease. *Microorganisms.* 2016 Jun 15;4(2):20.
- Sartor RB. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. *Gastroenterology.* 2010;139:1816-1819.
- Joossens M, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. *Gut.* 2011;1:2010.
- Martinez-Medina M, Garcia-Gil LJ. *Escherichia coli* in chronic inflammatory bowel diseases: an update on adherent invasive *Escherichia coli* pathogenicity. *World J Gastrointest Pathophysiol.* 2014;5(3):213.
- Chassaing B, Rolhion N, de Vallée A, Sa'ad YS, Prorok-Hamon M, Neut C, et al. Crohn disease-associated adherent-invasive *E. coli* bacteria target mouse and human Peyer's patches via long polar fimbriae. *J Clin Invest.* 2011;121(3):966-75.
- de Souza HL, de Carvalho VR, Romeiro FG, Sasaki LY, Keller R, Rodrigues J. Mucosa-associated but not luminal *Escherichia coli* is augmented in Crohn's disease and ulcerative colitis. *Gut Pathog.* 2012;4(1):21.
- Cruz CB, Souza MC, Serra PT, Santos I, Balieiro A, Pieri FA, et al. Virulence factors associated with pediatric shigellosis in Brazilian Amazon. *Biomed Res Int.* 2014; 2014.
- Zhang Y, Rowehl L, Krumsiek JM, Ormer EP, Shaikh N, Tarr PI, et al. Identification of candidate adherent-invasive *E. coli* signature transcripts by genomic/transcriptomic analysis. *PloS One.* 2015;10:e0130902.
- Lopez SM, Martinez MM, Busquets D. "Mucosa-associated *Faecalibacterium prausnitzii* and *Escherichia coli* co-abundance can distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease phenotypes". *Int J Med Microbiol.* 2014;304(4):464-475.
- Bitton A, Vutcovici M, Sewitch M, Suissa S, Brassard P. Mortality trends in Crohn's disease and ulcerative colitis: a population-based study in Quebec, Canada. *Inflamm Bowel Dis.* 2016;22(2):416-23.
- Sartor RB. Microbial influences in inflammatory bowel diseases. *Gastroenterology.* 2008;134(2):577-94.
- Sheehan D, Moran C, Shanahan F. The microbiota in inflammatory bowel disease. *J Gastroenterol.* 2015;50(5):495-507.
- Strauss J, Kaplan GG, Beck PL, Rioux K, Panaccione R, Devinney R, et al. Invasive potential of gut mucosa-derived *Fusobacterium nucleatum* positively correlates with IBD status of the host *Inflamm Bowel Dis.* 2011; 1971-1978
- Strober W. Adherent-invasive *E. coli* in Crohn disease: bacterial "agent provocateur". *J Clin Invest.* 2011 Mar 1; 121(3):841.
- Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. *ISME J.* 2012; 6(2):320-9.
- Iebba V, Conte MP, Lepanto MS, Di Nardo G, Santangelo F, Aloisi M, et al. Microevolution in *fimH* gene of mucosa-associated *Escherichia coli* strains isolated from pediatric patients with inflammatory bowel disease. *Infect Immun.* 2012; 80(4):1408-17.
- Bonnet M, Buc E, Sauvanet P, Darcha C, Dubois D, Pereira B, et al. Colonization of the human gut by *E. coli* and colorectal cancer risk. *Clin Cancer Res.* 2014; 20(4):859-67.
- Small CL, Reid-Yu SA, McPhee JB, Coombes BK. Persistent infection with Crohn's disease-associated adherent-invasive

- Escherichia coli* leads to chronic inflammation and intestinal fibrosis. Nat Commun. 2013; 4:1957.
24. Conte MP, Longhi C, Marazzato M, Conte AL, Aleandri M, Lepanto MS, et al. Adherent-invasive *Escherichia coli* (AIEC) in pediatric Crohn's disease patients: phenotypic and genetic pathogenic features. BMC Res Notes. 2014;7(1):748.
  25. Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, et al. Multidrug resistance is common in *Escherichia coli* associated with ileal Crohn's disease. Inflamm Bowel Dis. 2013; 19(1):141-50.
  26. Gombošová L, Lazúrová I, Zakuciová M, Čurová K, Kmet'ová M, Petrášová D, et al. Genes of intestinal *Escherichia coli* and their relation to the inflammatory activity in patients with ulcerative colitis and Crohn's disease. Folia Microbiol. 2011 Sep 1;56(5):367.
  27. Zhang Y, Rowehl L, Krumsiek JM, Orner EP, Shaikh N, Tarr PI, et al. Identification of candidate adherent-invasive *E. coli* signature transcripts by genomic/transcriptomic analysis. PLoS One. 2015;10(6): e0130902.